RE:RE:RE:Rapid Antigen Tests Very interesting development, TheeRock! Based on what I am reading in regards to the difference between approval and authorization, this device was authorized not approved. But that's a moot point because this is a device that would pair up well with AcuVid. As it can't be used to diagnose covid and as a positive result could be something other than covid ....having a secondary device like AcuVid would create a seamless, quick indicator for covid .....and in many instances reduce the waste concerns expressed by Why.
The only other question would be cost. Obviously you can't have only one Tiger Tech device if the intent is to quickly monitor large groups of individuals. If one device could be used to realistically monitor 10 to 15 individuals/hour a small school of 500 would probably need at least 50 of them. The fact that they are required to be used in conjunction with thermometers could also be a limitation in terms of time and cost ....although not necessarily an insurmountable one.
Cheers!
TheeRook wrote: The FDA did just that when they approved the
The Tiger Tech COVID Plus Monitor is intended for use by trained personnel to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19. “The FDA is committed to continuing to support innovative methods to fight the COVID-19 pandemic through new screening tools,” said Jeff Shuren, M.D., J.D., director of FDA’s Center for Devices and Radiological Health. “Combining use of this new screening device, that can indicate the presence of certain biomarkers, with temperature checks could help identify individuals who may be infected with the virus, thus helping to reduce the spread of COVID-19 in a wide variety of public settings, including healthcare facilities, schools, workplaces, theme parks, stadiums and airports.” The device is an armband with embedded light sensors and a small computer processor. The armband is wrapped around a person’s bare left arm above the elbow during use. The sensors first obtain pulsatile signals from blood flow over a period of three to five minutes. Once the measurement is completed, the processor extracts some key features of the pulsatile signals, such as pulse rate, and feeds them into a probabilistic machine learning model that has been trained to make predictions on whether the individual is showing certain signals, such as hypercoagulation in blood. Hypercoagulation is known to be a common abnormality in COVID-19 patients. The result is provided in the form of different colored lights used to indicate if an individual is demonstrating certain biomarkers, or if the result is inconclusive.
Whydunnit wrote:
THRM could make a dent in global covid if it starts making 25 million units a month but what the world needs is 500 million a week, if not more. I really hope if THRM clears all hurdles to commercialization that they find multiple partners around the world who can churn units out at massive numbers. I say that not even for the revenue it would generate but because it would help beat covid into submission.
Even if that happens something better is going to be needed. Imagine the plastic going into the garbage from 500 million tests a week, a mountain every day. Helping one problem but creating another. Sooner or later there's going to be
a rapid test that doesn't create a mountain of plastic garbage every day. Better yet, find a safe, surefire cure, science.